Skip to content
TrialScanner

NCT04590781

Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

Phase 1/Phase 2TerminatedXNCRLeadICLRCollaborator

Registry record

Lead sponsor
Xencor, Inc.
Conditions
Merkel Cell Carcinoma; Small Cell Lung Cancer
Primary completion
Mar 24, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04590781 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04590781: Safety and Efficacy of... | TrialScanner